

The opportunities and challenges of targeting pathways in HER2-positive BC beyond HER2

Roche-sponsored satellite symposium

3 May 2022, 18:00–19:00 CEST

*In person: Hamburg Hall,
hub27, Berlin, Germany*

LIVE STREAM AVAILABLE TO VIRTUAL ATTENDEES

Dear Colleagues,

I am pleased to invite you to a satellite symposium entitled *The opportunities and challenges of targeting pathways in HER2-positive BC beyond HER2*.

Please join Martine Piccart, Javier Cortés and myself for an interactive session where we will look for opportunities beyond targeting HER2 to improve outcomes in HER2-positive disease. We will explore novel therapeutic strategies in HER2+/HR+ BC, as well as the potential for combining HER2-targeted therapy with cancer immunotherapy.

We encourage you to submit your questions during the session for a lively discussion.

I look forward to seeing you in Berlin or via the live stream!

Dr Giampaolo Bianchini

Symposium Chair

Agenda

Welcome and introduction
Giampaolo Bianchini

HER2-positive disease: Seeing opportunity amongst the complexity
Javier Cortés

HER2+/HR+ disease: Our chance for improved patient outcomes
Martine Piccart

Cancer immunotherapy: exCITing prospects in HER2-positive breast cancer
Giampaolo Bianchini

Q&A
All

Close
Giampaolo Bianchini



Giampaolo Bianchini, MD
Ospedale San Raffaele,
Milan, Italy



Javier Cortés, MD, PhD
International Breast Cancer
Center (IBCC), Barcelona, Spain



Martine Piccart, MD, PhD
Institut Jules Bordet,
Brussels, Belgium